Human immunodeficiency virus type

Human immunodeficiency virus type 1 (infection with) (Vol. 67 1996)... [Pg.96]

M. A., Dorns, R. W., and Peiper, S. C. (1997). Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 71 6305-6314. [Pg.145]

Smyth, R. J., Yi, Y., Singh, A., and Collman, R. G. (1998). Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 isolate. J. Virol. 72 4478-4484. [Pg.145]

Luban J (2007) Cyclophihn A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol 81 1054-1061... [Pg.23]

Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase, J Virol 69 5087-5094... [Pg.23]

Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, BonhoefferS, Nowak MA, Hahn BH et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 117-122... [Pg.24]

CarriUo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ, Molla A (1998) In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 72 7532-7541 Chambers TJ, Nestorowicz A, Amberg SM, Rice CM (1993) Mutagenesis of the yellow fever virus NS2B protein effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol 67 6797-6807... [Pg.103]

Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW (2004) Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob Agents Chemother 48 4864 868... [Pg.105]

Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, CuHinan AB et al (1995) In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydrox-yethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 69 5228-5235 Patick AK (2006) Rhinovirus chemotherapy. Antiviral Res 71 391-396... [Pg.107]

The first lead compounds for non-nucleoside reverse transcriptase (RT) inhibitors (NNRTl) were discovered about 15 years ago (Pauwels et al. 1990 Merluzzi et al. 1990 Goldman et al. 1991 De Clercq 1993 Riibsamen-Waigmann et al. 1997). Since then they have become an important ingredient of the dmg combination schemes that are currently used in the treatment of human immunodeficiency virus type 1 (HlV-1) infections. Starting from the HEPT and TIBO derivatives, numerous classes of compounds have been described as NNRTIs. Four compounds (nevirapine, delavirdine, efavirenz and etravirine) have so far been approved for clinical use and several others are the subject of clinical trials (Balzarini 2004 Stellbrink 2007). [Pg.157]

De Clercq E (1993) HlV-l-spedfic RT inhibitors highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med Res Rev 13 229-258... [Pg.171]

Gibson W (1996) Structure and assembly of the virion. Intervirology 39 389 00 Goldman ME, Nunberg JH, O Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai IS, Hoffman JM et al. (1991) Pyridinone derivatives specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA... [Pg.172]

Zhou J, Yuan X, Dismuke D et al, (2004) Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation, J Virol 78 922-929... [Pg.176]

Many enveloped viruses share a common mechanism of fusion, mediated by a virus-encoded glycoprotein that contains heptad repeats in its extraceUnlar domain. Dnring the fnsion process, these domains rearrange to form highly structured and thermodynamically stable coiled-coils. Viruses encoding fusion proteins that have these domains inclnde members of the paramyxovirus family (e.g., respiratory syncytial virus, metapneumovirus, and measles virus), ebola virus, influenza, and members of the retroviridae (e.g., human T cell lenkemia virus type-1 and human immunodeficiency virus type-1, HlV-1). Peptide inhibitors of fusion that disrupt the... [Pg.178]

Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR (2007) Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 195 387-391 Dejucq N, Simmons G, Clapham PR (2000) T-ceU line adaptation of human immunodeficiency virus type 1 strain SF162 effects on envelope, vpu and macrophage-tropism. J Gen Virol 81 2899-2904... [Pg.194]

Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 661-666 Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gpl20. J Virol 74 8358-8367... [Pg.194]

Harrowe G, Cheng-Mayer C (1995) Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. Virology 210 490-494... [Pg.196]

He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, Weiss CD (2003) Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 77 1666-1671... [Pg.196]

Ho HT, Fan L, Nowicka-Sans B, McAuhffe B, li CB, Yamanaka G, Zhou N, Fang H, Dicker 1, Dalterio R, Gong YF, Wang T, Yin Z, Ueda Y, MatiskeUa J, Kadow J, Qapham P, Robinson J, Colonno R, Lin PF (2006) Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. [Pg.196]

Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labemardiere JL, Pacanowski J, Meynard JL, Hance AJ, Clavel E, Mammano E (2006) Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 80 8807-8819... [Pg.197]

Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR (2004) Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20), J Virol 78 4628 637 Lu M, Blacklow SC, Kim PS (1995) A tiimeric structural domain of the HlV-1 transmembrane glycoprotein, Nat Struct Biol 2 1075-1082... [Pg.198]

Pasture C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE (2006) Human immunodeficiency virus type 1 coreceptor switching V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 80 750-758... [Pg.200]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...